The multiplex crosstalk between non-coding RNAs, programmed cell death and related mechanisms: a dynamic duo in hematological malignancies.

IF 6 2区医学 Q1 ONCOLOGY

Cancer Cell International Pub Date : 2025-10-14 DOI:10.1186/s12935-025-03999-1

Mehrdad Hashemi, Niloufar Salimian, Nafiseh Sharifi, Pezhman Shafiei Asheghabadi, Zahra Zarearandi, Fatemeh Abdi, Saranaz SeyedAli Akbar, Reza Mohajer Shirazi, Mehrdad Bagheri Pozve, Armin Nikdehqan, Mehrandokht Nekavand, Zeinab Khazaei Koohpar, Russel J Reiter, Najma Farahani, Mobina Shariatzadeh, Mina Alimohammadi, Payman Rahimzadeh, Afshin Taheriazam, Maliheh Entezari, Kiavash Hushmandi

{"title":"The multiplex crosstalk between non-coding RNAs, programmed cell death and related mechanisms: a dynamic duo in hematological malignancies.","authors":"Mehrdad Hashemi, Niloufar Salimian, Nafiseh Sharifi, Pezhman Shafiei Asheghabadi, Zahra Zarearandi, Fatemeh Abdi, Saranaz SeyedAli Akbar, Reza Mohajer Shirazi, Mehrdad Bagheri Pozve, Armin Nikdehqan, Mehrandokht Nekavand, Zeinab Khazaei Koohpar, Russel J Reiter, Najma Farahani, Mobina Shariatzadeh, Mina Alimohammadi, Payman Rahimzadeh, Afshin Taheriazam, Maliheh Entezari, Kiavash Hushmandi","doi":"10.1186/s12935-025-03999-1","DOIUrl":null,"url":null,"abstract":"<p><p>Hematological malignancies, including leukemia, lymphoma, and multiple myeloma (MM), are cancers originating in the hematopoietic system, characterized by diverse pathogenesis and clinical features. Non-coding RNAs (ncRNAs) such as microRNAs (miRNAs) and long non-coding RNAs, play critical roles in regulating gene expression and influencing cell fate. Accumulating evidence indicates that ncRNAs are key modulators of programmed cell death (PCD) pathways, affecting tumor development, progression, and drug resistance in these malignancies. PCD, a precisely programmed and regulated cell death process, is vital for maintaining tissue homeostasis and preventing the proliferation of dangerous cells. NcRNAs are implicated in the primary mechanisms underlying the development of drug resistance. The evasion of PCD is a hallmark of cancer, and ncRNAs can significantly impact these pathways, with dysregulation observed across leukemia, lymphoma, and myeloma, influencing PCD pathways and clinical outcomes. Understanding the ncRNA-PCD interplay is crucial for developing novel therapeutic strategies and improving patient outcomes. This review explores the functions, regulatory mechanisms, and potential applications of ncRNAs in modulating PCD in hematological malignancies, particularly leukemias, providing insights for future anti-tumor therapies.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"25 1","pages":"350"},"PeriodicalIF":6.0000,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12523004/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12935-025-03999-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Hematological malignancies, including leukemia, lymphoma, and multiple myeloma (MM), are cancers originating in the hematopoietic system, characterized by diverse pathogenesis and clinical features. Non-coding RNAs (ncRNAs) such as microRNAs (miRNAs) and long non-coding RNAs, play critical roles in regulating gene expression and influencing cell fate. Accumulating evidence indicates that ncRNAs are key modulators of programmed cell death (PCD) pathways, affecting tumor development, progression, and drug resistance in these malignancies. PCD, a precisely programmed and regulated cell death process, is vital for maintaining tissue homeostasis and preventing the proliferation of dangerous cells. NcRNAs are implicated in the primary mechanisms underlying the development of drug resistance. The evasion of PCD is a hallmark of cancer, and ncRNAs can significantly impact these pathways, with dysregulation observed across leukemia, lymphoma, and myeloma, influencing PCD pathways and clinical outcomes. Understanding the ncRNA-PCD interplay is crucial for developing novel therapeutic strategies and improving patient outcomes. This review explores the functions, regulatory mechanisms, and potential applications of ncRNAs in modulating PCD in hematological malignancies, particularly leukemias, providing insights for future anti-tumor therapies.

Abstract Image

查看原文本刊更多论文

非编码rna、程序性细胞死亡及其相关机制之间的多重串扰：血液系统恶性肿瘤中的动态二人组。

血液系统恶性肿瘤，包括白血病、淋巴瘤和多发性骨髓瘤（MM），是起源于造血系统的癌症，具有多种发病机制和临床特征。非编码rna (ncRNAs)，如microRNAs （miRNAs）和长链非编码rna，在调节基因表达和影响细胞命运方面发挥着关键作用。越来越多的证据表明，ncrna是程序性细胞死亡（PCD）途径的关键调节剂，影响这些恶性肿瘤的发生、进展和耐药性。PCD是一个精确编程和调控的细胞死亡过程，对于维持组织稳态和防止危险细胞的增殖至关重要。ncrna与耐药发展的主要机制有关。PCD的逃避是癌症的一个标志，ncrna可以显著影响这些途径，在白血病、淋巴瘤和骨髓瘤中观察到失调，影响PCD途径和临床结果。了解ncRNA-PCD的相互作用对于开发新的治疗策略和改善患者预后至关重要。本文探讨了ncrna在血液恶性肿瘤，特别是白血病中调节PCD的功能、调控机制和潜在应用，为未来的抗肿瘤治疗提供见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Cell International ONCOLOGY-

CiteScore

10.90

自引率

1.70%

发文量

360

审稿时长

1 months

期刊介绍： Cancer Cell International publishes articles on all aspects of cancer cell biology, originating largely from, but not limited to, work using cell culture techniques. The journal focuses on novel cancer studies reporting data from biological experiments performed on cells grown in vitro, in two- or three-dimensional systems, and/or in vivo (animal experiments). These types of experiments have provided crucial data in many fields, from cell proliferation and transformation, to epithelial-mesenchymal interaction, to apoptosis, and host immune response to tumors. Cancer Cell International also considers articles that focus on novel technologies or novel pathways in molecular analysis and on epidemiological studies that may affect patient care, as well as articles reporting translational cancer research studies where in vitro discoveries are bridged to the clinic. As such, the journal is interested in laboratory and animal studies reporting on novel biomarkers of tumor progression and response to therapy and on their applicability to human cancers.